Chimaeric anti‐CD20 monoclonal antibody (rituximab) in post‐transplant B‐lymphoproliferative disorder following stem cell transplantation in children
Post‐transplant lymphoproliferative disorder (PTLD) after haemopoietic stem cell transplantation is a serious complication that occurs in 8–22% of patients with high‐risk factors. We retrospectively investigated tolerance and efficacy of humanized anti‐CD20 monoclonal antibody (rituximab) as first‐l...
Gespeichert in:
| Veröffentlicht in: | British journal of haematology 2001-10, Vol.115 (1), p.112-118 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 118 |
|---|---|
| container_issue | 1 |
| container_start_page | 112 |
| container_title | British journal of haematology |
| container_volume | 115 |
| creator | Faye, Albert Quartier, Pierre Reguerre, Yves Lutz, Patrick Carret, Anne‐Sophie Dehée, Axelle Rohrlich, Pierre Peuchmaur, Michel Matthieu‐Boué, Anne Fischer, Alain Vilmer, Etienne |
| description | Post‐transplant lymphoproliferative disorder (PTLD) after haemopoietic stem cell transplantation is a serious complication that occurs in 8–22% of patients with high‐risk factors. We retrospectively investigated tolerance and efficacy of humanized anti‐CD20 monoclonal antibody (rituximab) as first‐line treatment in 12 children with B‐cell PTLD. At diagnosis, eight patients had tumoral involvement. The other four patients had fever, associated with raised Epstein–Barr virus (EBV) viral load and monoclonal gammopathy. Rituximab was given at the dose of 375 mg/m2 once a week by intravenous infusion (1–9 infusions). Only 1/48 infusions was associated with a grade 2 clinical adverse event. Eight out of 12 (66%) patients responded to the treatment and were in complete remission. All patients without tumoral involvement responded to the treatment. A rapid decrease in fever within 1 week was observed in all responders. Non‐responders did not show any clinical response during the first week. Tumoral involvement and immunodepression seemed to be more marked in non‐responders. Rituximab was an effective and well‐tolerated treatment of B‐cell PTLD. Early treatment before tumoral involvement seemed to be the most effective approach. Lack of rapid response should lead to intensification of PTLD treatment. Pre‐emptive treatment should be considered and evaluated in further longitudinal multicentre studies. |
| doi_str_mv | 10.1046/j.1365-2141.2001.03041.x |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_72309077</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>72309077</sourcerecordid><originalsourceid>FETCH-LOGICAL-c5381-ee54f2d621d5984fee1d859da5c636522291bfb66f365f54f59deb22017ce04e3</originalsourceid><addsrcrecordid>eNqNkc9u1DAQxi0EokvhFZCFBKKHLLbz_8CBLoWCKnGBs-U4Y9YrJw52QndvfYTeebs-SSfdFStx4uQZz29Gn76PEMrZkrOseLdZ8rTIE8EzvhSM8SVLGZbbR2Txd_CYLBhjZYIL1Ql5FuMGwZTl_Ck54bwUIhNsQf6s1rZTEKymqh_t3c3t6qNgtPO91873yj18N77d0bfBjtMW6eaM2p4OPo6Ij0H1cXBI0XNs3a4b1n4I3lkDQY32N9DWRh9aCNR45_y17X_SOEJHNThHj_sI-36-rNfWtQH65-SJUS7Ci8N7Sn58uvi-ukyuvn3-svpwleg8rXgCkGdGtIXgbV5XmQHgbZXXrcp1gWYIIWremKYoDHYGWZxBIwTjpQaWQXpK3uzvouxfE8RRdjbO4lQPfoqyFCmrWVki-OofcOOngCZFyeuqYBWmgFC1h3TwMQYwcghoWthJzuScntzIOSQ5hyTn9ORDenKLqy8P96emg_a4eIgLgdcHQEWtnEHvtI1HLuO8rtNZ6Ps9d20d7P5bgDz_ejlX6T3Lb7r5</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>198608304</pqid></control><display><type>article</type><title>Chimaeric anti‐CD20 monoclonal antibody (rituximab) in post‐transplant B‐lymphoproliferative disorder following stem cell transplantation in children</title><source>MEDLINE</source><source>Wiley Online Library Free Content</source><source>Access via Wiley Online Library</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>Faye, Albert ; Quartier, Pierre ; Reguerre, Yves ; Lutz, Patrick ; Carret, Anne‐Sophie ; Dehée, Axelle ; Rohrlich, Pierre ; Peuchmaur, Michel ; Matthieu‐Boué, Anne ; Fischer, Alain ; Vilmer, Etienne</creator><creatorcontrib>Faye, Albert ; Quartier, Pierre ; Reguerre, Yves ; Lutz, Patrick ; Carret, Anne‐Sophie ; Dehée, Axelle ; Rohrlich, Pierre ; Peuchmaur, Michel ; Matthieu‐Boué, Anne ; Fischer, Alain ; Vilmer, Etienne</creatorcontrib><description>Post‐transplant lymphoproliferative disorder (PTLD) after haemopoietic stem cell transplantation is a serious complication that occurs in 8–22% of patients with high‐risk factors. We retrospectively investigated tolerance and efficacy of humanized anti‐CD20 monoclonal antibody (rituximab) as first‐line treatment in 12 children with B‐cell PTLD. At diagnosis, eight patients had tumoral involvement. The other four patients had fever, associated with raised Epstein–Barr virus (EBV) viral load and monoclonal gammopathy. Rituximab was given at the dose of 375 mg/m2 once a week by intravenous infusion (1–9 infusions). Only 1/48 infusions was associated with a grade 2 clinical adverse event. Eight out of 12 (66%) patients responded to the treatment and were in complete remission. All patients without tumoral involvement responded to the treatment. A rapid decrease in fever within 1 week was observed in all responders. Non‐responders did not show any clinical response during the first week. Tumoral involvement and immunodepression seemed to be more marked in non‐responders. Rituximab was an effective and well‐tolerated treatment of B‐cell PTLD. Early treatment before tumoral involvement seemed to be the most effective approach. Lack of rapid response should lead to intensification of PTLD treatment. Pre‐emptive treatment should be considered and evaluated in further longitudinal multicentre studies.</description><identifier>ISSN: 0007-1048</identifier><identifier>EISSN: 1365-2141</identifier><identifier>DOI: 10.1046/j.1365-2141.2001.03041.x</identifier><identifier>PMID: 11722420</identifier><identifier>CODEN: BJHEAL</identifier><language>eng</language><publisher>Oxford, UK: Blackwell Science Ltd</publisher><subject>Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy ; Antibodies, Monoclonal - therapeutic use ; Antibodies, Monoclonal, Murine-Derived ; Antilymphocyte Serum - therapeutic use ; Antineoplastic Agents - therapeutic use ; B-Lymphocytes ; Biological and medical sciences ; Blood. Blood coagulation. Reticuloendothelial system ; Bone marrow, stem cells transplantation. Graft versus host reaction ; children ; Epstein-Barr Virus Infections - drug therapy ; Hematology ; Hematopoietic Stem Cell Transplantation ; Humans ; Lymphoproliferative Disorders - diagnosis ; Lymphoproliferative Disorders - drug therapy ; Lymphoproliferative Disorders - surgery ; Medical sciences ; Pharmacology. Drug treatments ; Postoperative Period ; pre‐emptive ; PTLD ; Retrospective Studies ; Risk Factors ; Rituximab ; SCT ; Transfusions. Complications. Transfusion reactions. Cell and gene therapy ; Transplantation Conditioning</subject><ispartof>British journal of haematology, 2001-10, Vol.115 (1), p.112-118</ispartof><rights>2002 INIST-CNRS</rights><rights>Copyright Blackwell Scientific Publications Ltd. Oct 2001</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c5381-ee54f2d621d5984fee1d859da5c636522291bfb66f365f54f59deb22017ce04e3</citedby><cites>FETCH-LOGICAL-c5381-ee54f2d621d5984fee1d859da5c636522291bfb66f365f54f59deb22017ce04e3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1046%2Fj.1365-2141.2001.03041.x$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1046%2Fj.1365-2141.2001.03041.x$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,780,784,1417,1433,27924,27925,45574,45575,46409,46833</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=14119937$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/11722420$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Faye, Albert</creatorcontrib><creatorcontrib>Quartier, Pierre</creatorcontrib><creatorcontrib>Reguerre, Yves</creatorcontrib><creatorcontrib>Lutz, Patrick</creatorcontrib><creatorcontrib>Carret, Anne‐Sophie</creatorcontrib><creatorcontrib>Dehée, Axelle</creatorcontrib><creatorcontrib>Rohrlich, Pierre</creatorcontrib><creatorcontrib>Peuchmaur, Michel</creatorcontrib><creatorcontrib>Matthieu‐Boué, Anne</creatorcontrib><creatorcontrib>Fischer, Alain</creatorcontrib><creatorcontrib>Vilmer, Etienne</creatorcontrib><title>Chimaeric anti‐CD20 monoclonal antibody (rituximab) in post‐transplant B‐lymphoproliferative disorder following stem cell transplantation in children</title><title>British journal of haematology</title><addtitle>Br J Haematol</addtitle><description>Post‐transplant lymphoproliferative disorder (PTLD) after haemopoietic stem cell transplantation is a serious complication that occurs in 8–22% of patients with high‐risk factors. We retrospectively investigated tolerance and efficacy of humanized anti‐CD20 monoclonal antibody (rituximab) as first‐line treatment in 12 children with B‐cell PTLD. At diagnosis, eight patients had tumoral involvement. The other four patients had fever, associated with raised Epstein–Barr virus (EBV) viral load and monoclonal gammopathy. Rituximab was given at the dose of 375 mg/m2 once a week by intravenous infusion (1–9 infusions). Only 1/48 infusions was associated with a grade 2 clinical adverse event. Eight out of 12 (66%) patients responded to the treatment and were in complete remission. All patients without tumoral involvement responded to the treatment. A rapid decrease in fever within 1 week was observed in all responders. Non‐responders did not show any clinical response during the first week. Tumoral involvement and immunodepression seemed to be more marked in non‐responders. Rituximab was an effective and well‐tolerated treatment of B‐cell PTLD. Early treatment before tumoral involvement seemed to be the most effective approach. Lack of rapid response should lead to intensification of PTLD treatment. Pre‐emptive treatment should be considered and evaluated in further longitudinal multicentre studies.</description><subject>Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy</subject><subject>Antibodies, Monoclonal - therapeutic use</subject><subject>Antibodies, Monoclonal, Murine-Derived</subject><subject>Antilymphocyte Serum - therapeutic use</subject><subject>Antineoplastic Agents - therapeutic use</subject><subject>B-Lymphocytes</subject><subject>Biological and medical sciences</subject><subject>Blood. Blood coagulation. Reticuloendothelial system</subject><subject>Bone marrow, stem cells transplantation. Graft versus host reaction</subject><subject>children</subject><subject>Epstein-Barr Virus Infections - drug therapy</subject><subject>Hematology</subject><subject>Hematopoietic Stem Cell Transplantation</subject><subject>Humans</subject><subject>Lymphoproliferative Disorders - diagnosis</subject><subject>Lymphoproliferative Disorders - drug therapy</subject><subject>Lymphoproliferative Disorders - surgery</subject><subject>Medical sciences</subject><subject>Pharmacology. Drug treatments</subject><subject>Postoperative Period</subject><subject>pre‐emptive</subject><subject>PTLD</subject><subject>Retrospective Studies</subject><subject>Risk Factors</subject><subject>Rituximab</subject><subject>SCT</subject><subject>Transfusions. Complications. Transfusion reactions. Cell and gene therapy</subject><subject>Transplantation Conditioning</subject><issn>0007-1048</issn><issn>1365-2141</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2001</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkc9u1DAQxi0EokvhFZCFBKKHLLbz_8CBLoWCKnGBs-U4Y9YrJw52QndvfYTeebs-SSfdFStx4uQZz29Gn76PEMrZkrOseLdZ8rTIE8EzvhSM8SVLGZbbR2Txd_CYLBhjZYIL1Ql5FuMGwZTl_Ck54bwUIhNsQf6s1rZTEKymqh_t3c3t6qNgtPO91873yj18N77d0bfBjtMW6eaM2p4OPo6Ij0H1cXBI0XNs3a4b1n4I3lkDQY32N9DWRh9aCNR45_y17X_SOEJHNThHj_sI-36-rNfWtQH65-SJUS7Ci8N7Sn58uvi-ukyuvn3-svpwleg8rXgCkGdGtIXgbV5XmQHgbZXXrcp1gWYIIWremKYoDHYGWZxBIwTjpQaWQXpK3uzvouxfE8RRdjbO4lQPfoqyFCmrWVki-OofcOOngCZFyeuqYBWmgFC1h3TwMQYwcghoWthJzuScntzIOSQ5hyTn9ORDenKLqy8P96emg_a4eIgLgdcHQEWtnEHvtI1HLuO8rtNZ6Ps9d20d7P5bgDz_ejlX6T3Lb7r5</recordid><startdate>200110</startdate><enddate>200110</enddate><creator>Faye, Albert</creator><creator>Quartier, Pierre</creator><creator>Reguerre, Yves</creator><creator>Lutz, Patrick</creator><creator>Carret, Anne‐Sophie</creator><creator>Dehée, Axelle</creator><creator>Rohrlich, Pierre</creator><creator>Peuchmaur, Michel</creator><creator>Matthieu‐Boué, Anne</creator><creator>Fischer, Alain</creator><creator>Vilmer, Etienne</creator><general>Blackwell Science Ltd</general><general>Blackwell</general><general>Blackwell Publishing Ltd</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>H94</scope><scope>7X8</scope></search><sort><creationdate>200110</creationdate><title>Chimaeric anti‐CD20 monoclonal antibody (rituximab) in post‐transplant B‐lymphoproliferative disorder following stem cell transplantation in children</title><author>Faye, Albert ; Quartier, Pierre ; Reguerre, Yves ; Lutz, Patrick ; Carret, Anne‐Sophie ; Dehée, Axelle ; Rohrlich, Pierre ; Peuchmaur, Michel ; Matthieu‐Boué, Anne ; Fischer, Alain ; Vilmer, Etienne</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c5381-ee54f2d621d5984fee1d859da5c636522291bfb66f365f54f59deb22017ce04e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2001</creationdate><topic>Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy</topic><topic>Antibodies, Monoclonal - therapeutic use</topic><topic>Antibodies, Monoclonal, Murine-Derived</topic><topic>Antilymphocyte Serum - therapeutic use</topic><topic>Antineoplastic Agents - therapeutic use</topic><topic>B-Lymphocytes</topic><topic>Biological and medical sciences</topic><topic>Blood. Blood coagulation. Reticuloendothelial system</topic><topic>Bone marrow, stem cells transplantation. Graft versus host reaction</topic><topic>children</topic><topic>Epstein-Barr Virus Infections - drug therapy</topic><topic>Hematology</topic><topic>Hematopoietic Stem Cell Transplantation</topic><topic>Humans</topic><topic>Lymphoproliferative Disorders - diagnosis</topic><topic>Lymphoproliferative Disorders - drug therapy</topic><topic>Lymphoproliferative Disorders - surgery</topic><topic>Medical sciences</topic><topic>Pharmacology. Drug treatments</topic><topic>Postoperative Period</topic><topic>pre‐emptive</topic><topic>PTLD</topic><topic>Retrospective Studies</topic><topic>Risk Factors</topic><topic>Rituximab</topic><topic>SCT</topic><topic>Transfusions. Complications. Transfusion reactions. Cell and gene therapy</topic><topic>Transplantation Conditioning</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Faye, Albert</creatorcontrib><creatorcontrib>Quartier, Pierre</creatorcontrib><creatorcontrib>Reguerre, Yves</creatorcontrib><creatorcontrib>Lutz, Patrick</creatorcontrib><creatorcontrib>Carret, Anne‐Sophie</creatorcontrib><creatorcontrib>Dehée, Axelle</creatorcontrib><creatorcontrib>Rohrlich, Pierre</creatorcontrib><creatorcontrib>Peuchmaur, Michel</creatorcontrib><creatorcontrib>Matthieu‐Boué, Anne</creatorcontrib><creatorcontrib>Fischer, Alain</creatorcontrib><creatorcontrib>Vilmer, Etienne</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>British journal of haematology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Faye, Albert</au><au>Quartier, Pierre</au><au>Reguerre, Yves</au><au>Lutz, Patrick</au><au>Carret, Anne‐Sophie</au><au>Dehée, Axelle</au><au>Rohrlich, Pierre</au><au>Peuchmaur, Michel</au><au>Matthieu‐Boué, Anne</au><au>Fischer, Alain</au><au>Vilmer, Etienne</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Chimaeric anti‐CD20 monoclonal antibody (rituximab) in post‐transplant B‐lymphoproliferative disorder following stem cell transplantation in children</atitle><jtitle>British journal of haematology</jtitle><addtitle>Br J Haematol</addtitle><date>2001-10</date><risdate>2001</risdate><volume>115</volume><issue>1</issue><spage>112</spage><epage>118</epage><pages>112-118</pages><issn>0007-1048</issn><eissn>1365-2141</eissn><coden>BJHEAL</coden><abstract>Post‐transplant lymphoproliferative disorder (PTLD) after haemopoietic stem cell transplantation is a serious complication that occurs in 8–22% of patients with high‐risk factors. We retrospectively investigated tolerance and efficacy of humanized anti‐CD20 monoclonal antibody (rituximab) as first‐line treatment in 12 children with B‐cell PTLD. At diagnosis, eight patients had tumoral involvement. The other four patients had fever, associated with raised Epstein–Barr virus (EBV) viral load and monoclonal gammopathy. Rituximab was given at the dose of 375 mg/m2 once a week by intravenous infusion (1–9 infusions). Only 1/48 infusions was associated with a grade 2 clinical adverse event. Eight out of 12 (66%) patients responded to the treatment and were in complete remission. All patients without tumoral involvement responded to the treatment. A rapid decrease in fever within 1 week was observed in all responders. Non‐responders did not show any clinical response during the first week. Tumoral involvement and immunodepression seemed to be more marked in non‐responders. Rituximab was an effective and well‐tolerated treatment of B‐cell PTLD. Early treatment before tumoral involvement seemed to be the most effective approach. Lack of rapid response should lead to intensification of PTLD treatment. Pre‐emptive treatment should be considered and evaluated in further longitudinal multicentre studies.</abstract><cop>Oxford, UK</cop><pub>Blackwell Science Ltd</pub><pmid>11722420</pmid><doi>10.1046/j.1365-2141.2001.03041.x</doi><tpages>7</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0007-1048 |
| ispartof | British journal of haematology, 2001-10, Vol.115 (1), p.112-118 |
| issn | 0007-1048 1365-2141 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_72309077 |
| source | MEDLINE; Wiley Online Library Free Content; Access via Wiley Online Library; EZB-FREE-00999 freely available EZB journals |
| subjects | Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy Antibodies, Monoclonal - therapeutic use Antibodies, Monoclonal, Murine-Derived Antilymphocyte Serum - therapeutic use Antineoplastic Agents - therapeutic use B-Lymphocytes Biological and medical sciences Blood. Blood coagulation. Reticuloendothelial system Bone marrow, stem cells transplantation. Graft versus host reaction children Epstein-Barr Virus Infections - drug therapy Hematology Hematopoietic Stem Cell Transplantation Humans Lymphoproliferative Disorders - diagnosis Lymphoproliferative Disorders - drug therapy Lymphoproliferative Disorders - surgery Medical sciences Pharmacology. Drug treatments Postoperative Period pre‐emptive PTLD Retrospective Studies Risk Factors Rituximab SCT Transfusions. Complications. Transfusion reactions. Cell and gene therapy Transplantation Conditioning |
| title | Chimaeric anti‐CD20 monoclonal antibody (rituximab) in post‐transplant B‐lymphoproliferative disorder following stem cell transplantation in children |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-22T21%3A45%3A00IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Chimaeric%20anti%E2%80%90CD20%20monoclonal%20antibody%20(rituximab)%20in%20post%E2%80%90transplant%20B%E2%80%90lymphoproliferative%20disorder%20following%20stem%20cell%20transplantation%20in%20children&rft.jtitle=British%20journal%20of%20haematology&rft.au=Faye,%20Albert&rft.date=2001-10&rft.volume=115&rft.issue=1&rft.spage=112&rft.epage=118&rft.pages=112-118&rft.issn=0007-1048&rft.eissn=1365-2141&rft.coden=BJHEAL&rft_id=info:doi/10.1046/j.1365-2141.2001.03041.x&rft_dat=%3Cproquest_cross%3E72309077%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=198608304&rft_id=info:pmid/11722420&rfr_iscdi=true |